Prostate-specific antigen levels and subsequent prostate cancer: potential for screening

Area of Science:

• Urology
• Oncology
• Biomarkers

Background:

• Prostate-specific antigen (PSA) is a biomarker for prostatic disease, including prostate cancer.
• PSA monitoring aids in assessing treatment response and has been explored for prostate cancer detection.
• The association between baseline PSA levels and subsequent prostate cancer development requires further investigation.

Purpose of the Study:

• To evaluate the predictive value of a single serum PSA level for the future development of prostate cancer.
• To determine the temporal relationship between PSA levels and prostate cancer diagnosis.

Main Methods:

• Serum samples from 35 men who later developed prostate cancer and 35 matched controls were analyzed.
• Blood samples were collected in 1974 from a community-based serum bank.
• PSA levels were compared between cases and controls, considering time to diagnosis.

Main Results:

• Significantly higher PSA levels were observed in men who subsequently developed prostate cancer, up to 6 years prior to diagnosis.
• PSA levels decreased as the time to diagnosis increased.
• For cases diagnosed within 3 years, mean PSA was 16.2 mug/L vs. 2.4 mug/L for controls (P=0.002).
• For cases diagnosed between years 4-6, mean PSA was 9.6 mug/L vs. 1.3 mug/L for controls (p=0.0002).
• PSA levels >/= 4 mug/L showed 75% sensitivity and specificity up to 3 years prior to diagnosis.
• Up to 6 years prior, PSA levels demonstrated 67% sensitivity and 85% specificity.

Conclusions:

• Serum PSA levels are significantly elevated in men who later develop prostate cancer, indicating predictive potential.
• PSA testing may offer a valuable tool for early prostate cancer detection, potentially years before clinical diagnosis.
• Further controlled clinical trials are warranted to evaluate PSA screening for reducing prostate cancer mortality.